TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02167945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
Study: NCT03545256

Intervention type: PROCEDURE
Group type: OTHER
Intervention: outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
Description: The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth.
Study: NCT01363869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 2 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 4 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extracts 6 gm/day
Description: Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day.
Study: NCT02800655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS
Study: NCT04429815

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test for COVID-19.
Description: Serological test for COVID-19 performed as part of standard of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test for COVID-19.
Description: Serological test for COVID-19 performed as part of standard of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test for COVID-19.
Description: Serological test for COVID-19 performed as part of standard of care.
Study: NCT03797105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Obesity Intervention (FLOW)
Description: The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Obesity Intervention (FLOW)
Description: The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Obesity Intervention (FLOW)
Description: The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
Study: NCT04355598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine cream
Description: 2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate cream
Description: 2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: 2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Study: NCT03077932

Intervention type: OTHER
Group type: OTHER
Intervention: App Development and Open Pilot
Description: Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication.
Study: NCT03548441

Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.

Intervention type: OTHER
Intervention: Non-surgical management
Description: Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
Study: NCT02328898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cre8 Stent
Description: Comparison of the Resolute Integrity stent with the Cre8 stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity stent
Study: NCT02280213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct laryngoscopy 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIS
Description: Direct laryngoscopy 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIS
Description: Direct laryngoscopy 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL
Description: Direct laryngoscopy 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL
Description: Direct laryngoscopy 4
Study: NCT01442259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study: NCT05083455

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Enoxaparin
Description: Any enoxaparin dispensing claim is used as the reference group
Study: NCT03247894

Intervention type: OTHER
Intervention: Data search
Description: Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
Study: NCT00732745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT03652688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nightlife Safety Plans (NSP)
Description: A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fire Safety
Description: Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
Study: NCT03932201

Intervention type: DRUG
Intervention: Damoctocog alfa pegol (Jivi, Bay94-9027)
Description: Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Study: NCT00732745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02769624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Study: NCT00097357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 12 +/- 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Injection, SQ, Q12H, 12 +/- 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets, Oral, QD, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Placebo
Description: Injection, SQ, BID, 12 +/- 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Placebo
Description: Tablets, Oral, BID, 12 +/- 2 days
Study: NCT02940067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedEx
Description: A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
Study: NCT04205890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
Study: NCT02274610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel Polymeric Nanoparticle Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel Polymeric Nanoparticle Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Docetaxel
Study: NCT02887131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CT of the ankle
Description: during inversion and eversion mouvement, with Aquilion One Toshiba scanner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CT of the ankle
Description: during inversion and eversion mouvement, with Aquilion One Toshiba scanner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CT of the ankle
Description: during inversion and eversion mouvement, with Aquilion One Toshiba scanner
Study: NCT02986594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT01640457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVOCART® Disc plus
Description: Autologous Disc Chondrocyte Transplantation System (ADCT)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NOVOCART® Disc basic
Description: ADCT (Media with no active cell component)
Study: NCT01450176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride 0.2%
Description: 1 drop in each eye once daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bepotastine besilate ophthalmic solution 1.5%
Description: 1 drop in each eye twice daily for 2 weeks
Study: NCT05213988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Intermittent fasting meal pattern

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrates
Description: Bezafibrate 400 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate/High-Protein diet
Description: Low-calorie, low-carbohydrate, high-protein diet
Study: NCT04039997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRMeter
Description: teaching resuscitation with application of cpr feedback device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual chest compression
Description: Manual chest compression
Study: NCT01004302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventral capsular/ventral striatal gamma capsulotomy
Description: Comparison of active radiosurgical with sham radiosurgeries

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ventral capsular/ventral striatal gamma capsulotomy
Description: Comparison of active radiosurgical with sham radiosurgeries
Study: NCT02693314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarro-Dophilus EPS® (5 billion CFU/capsule)
Description: One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)
Description: One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
Study: NCT03261531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
Study: NCT01028625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Self-care Education
Description: Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.

Intervention type: OTHER
Group type: OTHER
Intervention: Heart Failure Self-care Education
Description: Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
Study: NCT00875355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study: NCT04432363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
Study: NCT04479800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral
Study: NCT04459455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contain COVID Anxiety SSI
Description: Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Remain COVID Free SSI
Description: This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
Study: NCT04082260

Intervention type: DRUG
Intervention: Alemtuzumab Injection [Lemtrada]
Description: Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.

Intervention type: DRUG
Intervention: Alemtuzumab Injection [Lemtrada]
Description: Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.

Intervention type: DRUG
Intervention: Alemtuzumab Injection [Lemtrada]
Description: Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.